Afatinib (Giotrif®) : The 1st choice in 1st-line

Afatinib: The 1st line choice in sequential therapy of NSCLC

 
 

Combined analysis of 2 non-interventional studies GioTag1 and UpSwinG2 showed encouraging activity in Asian Patients with EGFR M+ NSCLC3

Document ID: PC-VN-102652

23/09/2022

Author: Boehringer Ingelheim

123,000
Views

100k 340

NHỮNG NỘI DUNG LIÊN QUAN

 
PC-VN-102652
Production date: Sep 2022